Stock 688105 NANJING VAZYME BIOTECH CO.,LTD
Add to a list
To use this feature you must be a member
Log inSign up

Company Nanjing Vazyme Biotech Co.,Ltd

Equities

688105

CNE100004ZK3

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-07-16 pm EDT 		5-day change 1st Jan Change
20.35 CNY +1.50% Intraday chart for Nanjing Vazyme Biotech Co.,Ltd +8.53% -36.45%
10:38am Nanjing Vazyme Biotech's Unit Gets Approval to Sell Two Medical Devices in Europe MT
Jun. 14 Nanjing Vazyme Biotech Co.,Ltd(SHSE:688105) dropped from Shanghai Stock Exchange Health Care Sector Index CI

Business Summary

Nanjing Vazyme Biotech Co Ltd is China-based company principally engaged in biopharmaceuticals. The Company's main business is the technology research and development and product development of functional proteins such as enzymes, antigens, antibodies, and polymer organic materials. The Company's products include polymerase chain reaction (PCR), reverse transcription, gene sequencing series and other biological reagent products, quantum dot immunofluorescence reagents, latex enhanced immune turbidity reagents and colloidal gold immunochromatography reagents and other point-of-care testing (POCT) Diagnostic reagents and instruments.

Number of employees: 2,700

Sales per Business

CNY in Million2022Weight2023Weight Delta
Biological Reagent
73.4 %
1,437 40.3 % 944 73.4 % -34.33%
Diagnostic Reagent
19.3 %
2,010 56.3 % 248 19.3 % -87.65%
Technical Services
4.6 %
102 2.9 % 60 4.6 % -41.73%
Diagnostic Instrument
1.6 %
16 0.4 % 21 1.6 % +32.00%
Materials and Other Materials
0.9 %
- - 11 0.9 % -
Other Business
0.2 %
4 0.1 % 2 0.2 % -36.87%

Sales per region

CNY in Million2022Weight2023Weight Delta
China
96.7 %
3,335 93.6 % 1,005 96.7 % -69.88%
Overseas
3.3 %
230 6.4 % 34 3.3 % -85.07%

Managers

Managers TitleAgeSince
Lin Cao CEO
 Chief Executive Officer 45 12-02-29
Wen Xin Bi DFI
 Director of Finance/CFO 48 16-08-31
Guo Yang Zhang CHM
 Chairman 35 12-06-30
Juan Huang BRD
 Director/Board Member 38 15-04-30
Li Jun Zhang BRD
 Director/Board Member 41 12-02-29
Xiao Mei Hu BRD
 Director/Board Member 57 17-06-30
Xi Chen IRC
 Investor Relations Contact - -
Jin Huang SEC
 Corporate Secretary 33 20-05-27

Members of the board

Members of the board TitleAgeSince
Kuan Yun Xia BRD
 Director/Board Member 62 20-05-27
Jiang Nan Cai BRD
 Director/Board Member 67 20-05-27
Lin Cao CEO
 Chief Executive Officer 45 12-02-29
Xiao Mei Hu BRD
 Director/Board Member 57 17-06-30
Li Jun Zhang BRD
 Director/Board Member 41 12-02-29
Bo Tang BRD
 Director/Board Member 44 20-02-29
Wei Dong BRD
 Director/Board Member 60 20-09-02
Guo Yang Zhang CHM
 Chairman 35 12-06-30
Su Feng BRD
 Director/Board Member 41 17-04-30
Juan Huang BRD
 Director/Board Member 38 15-04-30

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 403,021,135 85,145,460 ( 21.13 %) 3,011,135 ( 0.7471 %) 21.13 %

Shareholders

NameEquities%Valuation
China Life Private Equity Investment Co. Ltd.
18.55 %
30,957,960 18.55 % 85 M ¥
Qi Yang
13.06 %
21,803,890 13.06 % 60 M ¥
Danen Capital Co. Ltd.
8.854 %
14,778,883 8.854 % 41 M ¥
Nanjing Nuotai Venture Capital Partnership LP
7.587 %
12,663,330 7.587 % 35 M ¥
GF Xinde Investment Management Co. Ltd.
5.073 %
8,468,073 5.073 % 23 M ¥
Kejing Yang
2.802 %
4,676,919 2.802 % 13 M ¥
GF Fund Management Co., Ltd.
2.666 %
4,449,347 2.666 % 12 M ¥
Hwabao WP Fund Management Co., Ltd.
2.122 %
3,542,610 2.122 % 10 M ¥
Zhijun Jia
1.454 %
2,426,970 1.454 % 7 M ¥
Shenzhen Share Investment LP
1.281 %
2,137,508 1.281 % 6 M ¥
NameEquities%Valuation
Lin Cao
90.30 %
210,483,354 90.30 % 580 M ¥
Ying Duan
3.335 %
7,773,247 3.335 % 21 M ¥

Company contact information

Nanjing Vazyme Biotech Co., Ltd.

Building D2 Hongfeng Science Park, Kechuang Road

210033, Nanjing

+

http://www.vazyme.com
address Nanjing Vazyme Biotech Co.,Ltd(688105)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per Business

Sales per region

Ratings for Nanjing Vazyme Biotech Co.,Ltd

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
20.35
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
NANJING VAZYME BIOTECH CO.,LTD Stock Nanjing Vazyme Biotech Co.,Ltd
-36.45% 1.1B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+56.97% 848B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+31.64% 627B
JOHNSON & JOHNSON Stock Johnson & Johnson
-0.58% 363B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.41% 318B
ABBVIE INC. Stock AbbVie Inc.
+12.32% 299B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.51% 243B
NOVARTIS AG Stock Novartis AG
+16.72% 225B
AMGEN INC. Stock Amgen Inc.
+16.07% 179B
PFIZER, INC. Stock Pfizer, Inc.
+3.18% 167B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 688105 Stock
  4. Company Nanjing Vazyme Biotech Co.,Ltd